SNY

GSK and Sanofi, two major European pharmaceutical companies, are compared across growth drivers, pipelines, and valuations. GSK shows strong specialty medicines growth (14% in H1 2026) with expanding oncology and HIV franchises, while Sanofi benefits from blockbuster Dupixent sales (up 28.6%) and stronger near-term earnings growth. Despite both holding Hold ratings, Sanofi appears better positioned due to superior earnings growth outlook, favorable valuation metrics, and positive estimate revisions, though it faces vaccine sales headwinds and heavy Dupixent reliance.

Over 200 companies are advancing more than 240 pipeline Alzheimer's disease therapies across various clinical development stages. The market is being driven by an aging population, rising disease prevalence, and the emergence of disease-modifying therapies that enable earlier intervention and biomarker-guided care. Two therapies have recently received FDA approval: KISUNLA (donanemab) from Eli Lilly and LEQEMBI (lecanemab-irmb) from Eisai/Biogen, both targeting amyloid plaques to slow disease progression.

GSK is focusing on newer specialty medicines and vaccines to offset pressure from older products and drive long-term growth. Recent product launches including Blenrep, Jemperli, and Arexvy are expected to become major revenue contributors, with Blenrep anticipated as a key growth driver over 3-4 years.

The company has doubled its phase II and III blockbuster-potential assets since 2022 and expects sales exceeding £40 billion by 2031. However, GSK faces significant competition from major pharmaceutical companies and must navigate patent expirations, particularly in HIV.

Despite declining Eylea sales, Regeneron's strong performance is driven by Dupixent, a blockbuster drug developed with Sanofi that generated $6 billion in global sales with 38% year-over-year growth. The company's Q2 revenue grew 17% to $4.3 billion, with Dupixent collaboration revenue jumping 51%. While Dupixent faces biosimilar competition in the early 2030s, Regeneron plans to defend its market position through improved formulations, pipeline replacements, and promising candidates like olatorepatide in the weight-loss market.

Nektar Therapeutics (NKTR) initiated two Phase III studies (ZENITH AD-1 and ZENITH AD-2) for rezpeg in atopic dermatitis in July 2026, with top-line data expected mid-2028. The company plans Phase III studies for alopecia areata in early 2027 and expects Type I diabetes data in 2027.

Rezpeg, a self-administered injection that activates regulatory T-cells, faces competition from established players like Sanofi/Regeneron's Dupixent. NKTR trades at a valuation discount to the industry with a Zacks Rank #3 (Hold) rating.

Sanofi and AbbVie are compared as major pharmaceutical companies with different growth drivers. Sanofi, powered by Dupixent's strong performance and newer medicines, trades at a lower valuation (7.82x forward earnings) with a 4.5% dividend yield, while AbbVie relies on Skyrizi and Rinvoq to offset Humira's decline but trades at 19.62x forward earnings with a 2.5% yield. Analysts favor Sanofi (Zacks Rank #3 Hold) over AbbVie (Rank #4 Sell) due to its attractive valuation and upgraded growth outlook.

Matchpoint Therapeutics appointed John O'Malley, M.D., Ph.D., as Chief Medical Officer to lead clinical development of its pipeline of first-in-class oral small molecules for autoimmune and inflammatory diseases. The appointment follows the company's recent $150M Series B financing. Dr. O'Malley brings extensive immunology expertise from previous roles at CRISPR Therapeutics and Sanofi.

The article compares Moderna and Vertex Pharmaceuticals as investment options for 2026. Moderna is expanding its mRNA platform into RSV and oncology but faces profitability challenges with a $2.8B net loss in FY2025 and 39.2% revenue decline.

Vertex dominates the cystic fibrosis market with $12.1B revenue, 32.7% net margins, and $3.2B free cash flow, while diversifying into gene therapy and pain management. The author recommends Vertex for its established profitability and growing pipeline, though acknowledges Moderna's long-term platform potential.

Teva Pharmaceutical Industries announced FDA approval of Weltruza (olanzapine) extended-release injectable suspension, the first once-monthly subcutaneous formulation for treating schizophrenia in adults. The drug will launch in the U.S. in coming weeks with three dosage strengths and requires no loading doses or post-injection monitoring. This approval expands Teva's schizophrenia portfolio alongside its existing Uzedy product, which generated $140 million in sales in the first half of 2026.

Retension Pharmaceuticals, a clinical-stage biopharmaceutical company developing treatments for hypertension and cardiovascular diseases, priced its IPO at $12 per share, raising $45 million gross proceeds. The company plans to use the funds to complete Phase 2b trials and prepare for Phase 3 trials of its lead candidate RTN-001. Trading on Nasdaq under ticker RTSN is expected to begin October 9, 2026.

Sanofi announced the publication of its Q3 2026 aide-mémoire on October 6, 2026, with full quarterly results to follow on October 30, 2026. The company also announced expansions of strategic alliances with Regeneron for next-generation immunology antibodies and with Cheplapharm for mature medicines partnerships.

Sanofi announced the availability of its Q3 2026 results aide-mémoire on October 6, 2026, with full results to be published on October 30, 2026. The company also announced expansions of strategic partnerships with Regeneron for next-generation immunology antibodies and with Cheplapharm for mature medicines.

Sanofi and Regeneron have expanded their longstanding alliance to co-develop four next-generation long-acting antibodies targeting type II inflammation. Regeneron will receive $1 billion upfront and up to $7 billion in milestone payments, with both companies equally sharing development costs and future profits. The collaboration builds on their successful Dupixent partnership, which generated €9.3 billion in sales in H1 2026 and is projected to reach €25 billion by 2030.

The global Enzyme Replacement Therapy (ERT) market is projected to grow from USD 12.24 billion in 2025 to USD 27.90 billion by 2035, with a CAGR of 8.59%. Growth is driven by early identification of rare lysosomal storage disorders, increased newborn screening, orphan drug incentives, and expanding healthcare access.

North America leads with 38.76% market share, while Asia-Pacific shows the fastest growth at 9.43% CAGR. Imiglucerase dominates products, and Gaucher disease represents the largest therapeutic condition.